At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841
In Brief
A Phase 1 clinical trial evaluating PF-06700841 oral solution/suspension, Placebo, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 96 participants across 1 site.
Detailed Summary
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).
Study Details
Timeline
Interventions
Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
Matching placebo given during the single ascending and multiple dose periods
PF-06700841 tablet formulation administered during the bioavailability / food effect investigation